• If you are wondering whether Sarepta Therapeutics' current share price reflects its true worth, you are not alone. The recent moves have put valuation firmly in the spotlight.
• The stock last closed at US$16.76, with returns of an 11.2% decline over 7 days, 21.1% decline over 30 days, 21.4% decline year to date, 84.3% decline over 1 year, 89.2% decline over 3 years, and 80.2% decline over 5 years.
• Recent news flow around Sarepta has focused on its position in the pharmaceuticals and biotech space and how market sentiment is responding to its pipeline developments and regulatory milestones. This context helps explain why the share price has been so volatile, as investors reassess both the risks and potential rewards.
• On our valuation checks, Sarepta scores 5 out of 6 for being assessed as undervalued. You can see this in more detail in its valuation score of 5. Next, we will walk through the key valuation methods behind that result and then look at an even richer way to think about value that pulls everything together at the end of the article.

Approach 1: Sarepta Therapeutics Discounted Cash Flow (DCF) Analysis

A DCF model estimates what a company could be worth by projecting its future cash flows and then discounting those back into today’s dollars.

For Sarepta Therapeutics, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is a loss of $356.0 million, so the starting point is negative. Analysts then provide explicit free cash flow estimates for the next few years, and Simply Wall St extends those projections further, including a projected free cash flow of $466 million in 2030. Additional estimates run out to 2035, all in $ and all below $1b, so still in the millions range.

Bringing all of those projected cash flows back to today using a discount rate produces an estimated intrinsic value of about $77.44 per share. Compared with the recent share price of $16.76, the model implies the stock trades at roughly a 78.4% discount, which points to it being significantly undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Sarepta Therapeutics is undervalued by 78.4%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Sarepta Therapeutics Price vs Sales

For companies where earnings are less reliable or negative, the P/S ratio is often a cleaner way to think about value because it focuses on revenue rather than profit swings. Investors tend to accept a higher or lower P/S depending on what they expect for future growth and how risky they think those sales are, so there is no single “right” number.

Sarepta Therapeutics currently trades on a P/S of 0.80x, compared with the Biotechs industry average of 12.43x and a peer average of 14.12x. Simply Wall St also calculates a proprietary “Fair Ratio” of 0.85x for Sarepta, which reflects factors such as earnings growth, profit margins, industry, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison with industry or peer averages because it adjusts for the company’s own profile rather than assuming all biotechs deserve the same multiple. Setting Sarepta’s current 0.80x P/S against the 0.85x Fair Ratio suggests the shares are somewhat cheap on this revenue based view, as the gap between the two is larger than 0.10x.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Sarepta Therapeutics Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let us introduce Narratives, which are simply your story about Sarepta Therapeutics linked to clear numbers like your assumed fair value and expectations for future revenue, earnings and margins.

A Narrative takes what you believe about Sarepta’s Elevidys execution, pipeline breadth, safety profile and capacity build out, turns that into a financial forecast, then ties it directly to a fair value that you can compare with today’s share price to decide whether the stock looks expensive or cheap to you.

On Simply Wall St’s Community page, used by millions of investors, Narratives are an easy tool where you can either use shared examples or set your own assumptions, and they automatically refresh when new data such as earnings, clinical results, regulatory updates or analyst targets, like fair values around US$21.43, US$40.10 or US$70.00 for Sarepta, are published.

That means two investors can look at the same company and reach different but well structured conclusions. For example, one may focus on cautious revenue assumptions and a lower fair value closer to US$21.43, and another may focus on stronger Elevidys and pipeline contributions with a higher fair value nearer US$70.00, all within a framework that makes those differences transparent rather than emotional.

Do you think there's more to the story for Sarepta Therapeutics? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.